The obesity epidemic is bursting at the seams we said on May 23.

According to the World Health Organization, obesity has tripled since 1975.  More than 1.9 billion adults were overweight, as of 2016, with more than 650 million considered obese. By 2030, about 20% of the global population will be obese, according to the National Centers for Biotechnology Information.  

While the numbers are off the scales, it also created massive investment opportunities in stocks like Eli Lilly, Novo Nordisk and Viking Therapeutics.

It also created opportunity for Structure Therapeutics (GPCR), which we also highlighted on May 23. According to JPMorgan, GPCR was an overlooked player in the weight loss treatment market. The firm also had an overweight rating on the stock, with a price target of $65.

At the time, GPCR traded at $37. Today, it’s up to $55.07 and could race to higher highs.

For one, it’s moving forward with its 36-week Phase 2b obesity study later this year. Two, GPCR believes its GSBR-1290 obesity treatment is uniquely positioned as an oral, non-peptide small molecule GLP-1 receptor agonist that can be manufactured at scale and significantly help address the growing obesity epidemic, which current peptide GLP-1s are not able to do.”

Even better, Goldman Sachs just raised its market prediction to $130 billion from $100 billion.